OpenAI announced Wednesday that it has acquired Orchestra Bio, a software platform built to help biopharmaceutical teams coordinate the many moving parts of drug development, in a move that pushes the company further into the life sciences industry.
OpenAI said it plans to combine Orchestra Bio with Rosalind, its existing set of life-sciences models and tools, so that its artificial-intelligence systems can support more of the process that sits between early scientific research and the later steps of evaluating whether a potential treatment actually works. Until now, much of OpenAI's work in this area has focused on generating research hypotheses and helping scientists analyze existing data. The Orchestra Bio deal is intended to move the company closer to the operational work of drug development itself, the stage where many promising ideas stall because of the complexity of coordinating trials, data and regulatory requirements.
The acquisition came amid a busy day across the artificial-intelligence industry. Anthropic put forward a proposal for federal legislation aimed at AI safety, adding to an ongoing debate in Washington over how closely the government should regulate fast-moving AI systems. Separately, OpenAI said its newest model, GPT-6.1 Sol, made significant gains on a benchmark that tests how well AI systems can migrate old software written in COBOL, a decades-old programming language still widely used by banks and government agencies; the company said the new model's accuracy on that task jumped to nearly 98 percent at its highest reasoning setting, up sharply from the prior model, while also cutting costs. Notion, the workplace software company, also rolled out an updated AI agent capable of working on a single task for more than 24 hours at a stretch, a sharp jump from the roughly five minutes its previous system could sustain.
Taken together, the day's announcements reflect how major AI companies are racing to move beyond chatbots and research assistants into tools meant to handle long, complex, real-world workflows, whether that means running a drug-development program, migrating a bank's decades-old computer code, or completing a day-long project without human intervention at every step.
Industry watchers will be looking for details on how OpenAI integrates Orchestra Bio's coordination tools with its existing life-sciences work, and for how Washington responds to Anthropic's new push for federal AI safety legislation.
What does Orchestra Bio do?
It is a platform designed to help biopharmaceutical teams coordinate the many steps involved in drug development.
Why does this matter beyond OpenAI?
It's part of a broader shift across the AI industry toward tools built to handle long, complex, real-world tasks rather than just answering questions or generating ideas.